default author photo

Anna V. Tinker

BC Cancer

Canada

SCHOLARLY PAPERS

3

DOWNLOADS

301

TOTAL CITATIONS

0

Scholarly Papers (3)

1.

Survival Prognostic and Surrogate Values of the Early Modeled Ca-125 Kelim Score in First-Line Treatment of Ovarian Cancer: Results from The Gcig Individual Patient Data Meta-Analysis

Number of pages: 38 Posted: 13 Apr 2022
University of Claude Bernard Lyon 1 - UCBL/HCL, Université Lyon 1 - Faculty of Medicine Lyon-Sud, University of Glasgow - Beatson West of Scotland Cancer Centre, Jikei University - School of Medicine, BC Cancer, The Norwegian Radium Hospital Montebello, University of Claude Bernard Lyon 1 - Medical Oncology Department, European Society of Gynaecological Oncology (ESGO), Université Lyon 1, Université Lyon 1 - Faculty of Medicine Lyon-Sud, Institut de Cancérologie des Hospices Civils de Lyon - Centre Hospitalier Lyon-Sud, University of Paris-Saclay - Institut Gustave Roussy, Imperial College London, University of Glasgow - Beatson West of Scotland Cancer Centre, Foundation for Biomedical Research and Innovation (FBRI), University of Western Ontario - London Health Sciences Centre, University of Glasgow, College of Medical, Veterinary & Life Sciences, Beatson West of Scotland Cancer Centre, Cancer Research UK Clinical Trials Unit, Institut Curie - Department of BiostatisticsUniversity of Paris - Faculty of Medicine Paris and University College London - MRC Clinical Trials Unit
Downloads 103 (674,591)

Abstract:

Loading...

ovarian neoplasms, antigen, CA-125, kinetics, chemosensitivity, prognostic biomarker, surrogacy

2.

Avelumab Alone or in Combination with Chemotherapy vs Chemotherapy Alone in Platinum-Resistant or Platinum-Refractory Ovarian Cancer (JAVELIN Ovarian 200): A Randomised, Open-Label, Phase 3 Study

Number of pages: 52 Posted: 28 Oct 2020
ARCAGY-GINECO, Saitama Medical University International Medical Center (SIMC), University College London - UCL Cancer Institute, University of Toronto - Princess Margaret Cancer Centre, University College London - UCL Cancer Institute, University of Claude Bernard Lyon 1 - Medical Oncology Department, Cabrini Hospital - Department of Medical Oncology, Ospedale San Giovanni - Oncology Institute of Southern Switzerland (IOSI), National Cancer Center Hospital - Department of Breast and Medical Oncology, Government of the United Kingdom - Royal Marsden NHS Foundation Trust, Université Paris XI Sud - Gustave Roussy Cancer Campus, BC Cancer, University of Ulsan - Department of Oncology, Poznan University of Medical Sciences - Department of Oncology, National Cancer Center - Center for Uterine CancerNational Cancer Center, Korea - Center for Gynecologic Cancer, Willamette Valley Cancer Institute and Research Center, Pfizer Oncology, Pfizer Oncology, Pfizer, Inc. - Pfizer Global Biometrics and Data Management, Pfizer Oncology and University of Arizona - College of Medicine, Arizona Oncology (US Oncology Network)
Downloads 101 (684,672)

Abstract:

Loading...

ovarian cancer, Avelumab, PD-L1, Phase 3, immune checkpoint inhibitor

3.

A Phase II Study of Durvalumab and Tremelimumab in Patients with Advanced Rare Cancer

Number of pages: 41 Posted: 12 Jun 2024
The Hospital for Sick Children, BC Cancer, University of Ottawa - Ottawa Hospital Research Institute, University of Montreal - Notre-Dame Hospital, Juravinski Hospital - Cancer Centre, Western University, Canada, Cross Cancer Institute, University of British Columbia (UBC), CancerCare Manitoba, University of British Columbia (UBC), University of British Columbia (UBC), University of Toronto - University Health Network, University of Toronto - Princess Margaret Cancer Centre, University of Montreal - Notre-Dame Hospital, University of Ottawa - Ottawa Hospital Research Institute, University of Toronto - Princess Margaret Cancer Centre, University of Toronto - University Health Network, Juravinski Hospital - Cancer Centre, Canadian Cancer Trials Group, Canadian Cancer Trials Group, Canadian Cancer Trials Group and Canadian Cancer Trials Group
Downloads 97 (704,534)

Abstract:

Loading...

checkpoint inhibitors, rare cancers, ovarian carcinoma